In addition to confirming hepatic triglyceride sensitivity to previously identified deregulations in NAFLD, the SteatoNet identified novel candidate mechanisms, such as cholesterol transport, ketone body metabolism and regulatory functions of FXR, LXR and SREBP-2, that require experimental focus in the future. Here, SREBF2 is linked to metabolic dysfunction-associated steatotic liver disease.